Journal of medicinal and pharmaceutical chemistry 2009-08-13

Synthesis and evaluation of 3-aroylindoles as anticancer agents: metabolite approach.

Yu-Shan Wu, Mohane Selvaraj Coumar, Jang-Yang Chang, Hsu-Yi Sun, Fu-Ming Kuo, Ching-Chuan Kuo, Ying-Jun Chen, Chi-Yen Chang, Chia-Ling Hsiao, Jing-Ping Liou, Ching-Ping Chen, Hsien-Tsung Yao, Yi-Kun Chiang, Uan-Kang Tan, Chiung-Tong Chen, Chang-Ying Chu, Su-Ying Wu, Teng-Kuang Yeh, Chin-Yu Lin, Hsing-Pang Hsieh

Index: J. Med. Chem. 52 , 4941, (2009)

Full Text: HTML

Abstract

BPR0L075 (2) is a potential anticancer drug candidate designed from Combretastatin A-4 (1) based on the bioisosterism principle. Metabolites of 2, proposed from in vitro human microsome studies, were synthesized, leading to the identification of metabolite-derived analogue 10 with 40-350 pM potency against various cancer cell lines. Insights gained from the major inactive metabolite of 2 led to the development of 29, with better pharmacokinetics and improved potency in the tumor xenograft model than 2.

Related Compounds

  • 6-Methoxyindole
  • Colchicine

Related Articles:

Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators.

2011-08-11

[J. Med. Chem. 54 , 5320, (2011)]

Discovery of a novel class of PPARdelta partial agonists.

2008-09-15

[Bioorg. Med. Chem. Lett. 18 , 5018, (2008)]

Synthesis of 3,3-diindolyl oxyindoles efficiently catalysed by FeCl3 and their in vitro evaluation for anticancer activity.

2010-09-01

[Bioorg. Med. Chem. Lett. 20 , 5229, (2010)]

Indole ring oxidation by activated leukocytes prevents the production of hypochlorous acid.

2005-11-01

[Braz. J. Med. Biol. Res. 38(11) , 1575-83, (2005)]

Identification of potent ITK inhibitors through focused compound library design including structural information

2010-01-01

[Bioorg. Med. Chem. Lett. 20 , 6998, (2010)]

More Articles...